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Aim To determine the diagnostic yield and criteria that 
could help to classify and interpret the copy number varia-
tions (CNVs) detected by chromosomal microarray (CMA) 
technique in patients with congenital and developmental 
abnormalities including dysmorphia, developmental delay 
(DD) or intellectual disability (ID), autism spectrum disor-
ders (ASD) and congenital anomalies (CA).
Method CMA analysis was performed in 337 patients with 
DD/ID with or without dysmorphism, ASD, and/or CA. In 30 
of 337 patients, chromosomal imbalances had previously 
been detected by classical cytogenetic and molecular cy-
togenetic methods.
Results In 73 of 337 patients, clinically relevant variants 
were detected and better characterized. Most of them 
were >1 Mb. Variants of unknown clinical significance 
(VOUS) were discovered in 35 patients. The most common 
VOUS size category was <300 kb (40.5%). Deletions and de 
novo imbalances were more frequent in pathogenic CNV 
than in VOUS category. CMA had a high diagnostic yield 
of 43/307, excluding patients previously detected by other 
methods.
Conclusion CMA was valuable in establishing the diag-
nosis in a high proportion of patients. Criteria for classi-
fication and interpretation of CNVs include CNV size and 
type, mode of inheritance, and genotype-phenotype cor-
relation. Agilent ISCA v2 Human Genome 8x60 K oligonu-
cleotide microarray format proved to be reasonable reso-
lution for clinical use, particularly in the regions that are 
recommended by the International Standard Cytogenom-
ic Array (ISCA) Consortium and associated with well-estab-
lished syndromes.
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Patients with developmental delay or intellectual disabil-
ity (DD/ID), autism spectrum disorders (ASD), and con-
genital anomalies (CA) account for the largest proportion 
of cytogenetic testing due to their high prevalence in the 
population. More than 80% of the chromosomal aberra-
tions found in ID/DD or ASD are submicroscopic and not 
detected by classical cytogenetic methods. Chromosomal 
microarray (CMA) is used as the first test to detect copy 
number variations (CNVs) that are major cause of these 
disorders. Large cohort studies of patients with DD/ID, CA, 
or ASD screened by microarray found a diagnostic yield of 
14–20% compared with ~ 3% for the standard G-banded 
karyotype (1,2).
The resolution level of the CMA has no limit, ie, it depends 
on the size and distance between the test probes on the 
array. Today, there are a number of commercially available 
array platforms, which differ in genome coverage, resolu-
tion, and application. A higher array resolution can mean 
not only an increased yield of clinical genetic diagnosis, but 
also a higher level of detection of benign CNVs or variants of 
unknown clinical significance (VOUS). Therefore, the correct 
choice of the resolution array platform that balances sensi-
tivity and specificity is very important for clinical practice.
Defining the pathogenicity of CNVs is the major difficulty 
in the interpretation of the array results. The usual criteria 
used in the interpretation of the clinical relevance of a CNV 
are inheritance, size, type, and gene content.
In this study, we present the CMA analysis of 337 patients 
with DD/ID with or without dysmorphic features, ASD and/
or CA. In 30 patients, chromosomal imbalances had been 
previously detected by classical cytogenetic and molecu-
lar cytogenetic methods. These patients were analyzed 
by CMA to define more precisely the breakpoints and the 
gene content of the rearrangements and to clarify if there 
were any additional CNVs. The aim of the study was to de-
termine the diagnostic yield of the CMA analysis on the 
remaining 307 patients and criteria that could help in clas-
sification and interpretation of the CNVs detected.
PAtIentS And MethodS
Patients
The analysis included 337 unrelated patients from Croatia, 
referred to the Department of Medical Genetics and Re-
productive Health, Children’s Hospital Zagreb, Univer-
sity of Zagreb, School of Medicine, who were diag-
nosed by clinical geneticists or pediatricians to have DD/
ID, ASD, CA, or a combination of those features. We divided 
the patients according to the main clinical features into six 
groups as follows: ID/DD, ASD, CA with/without dysmor-
phism; ID/DD, CA with/without dysmorphism; ID/DD, ASD 
with or without dysmorphism; ID/DD with/without dys-
morphism; CA with/without dysmorphism; and ASD with/
without dysmorphism. The median age of patients at ex-
amination was 7 years (range: one months to 25 years). 
Samples were analyzed by CMA in the period between 
January 2016 and April 2017. In 30 patients, chromosomal 
imbalances had already been detected by high resolution 
conventional cytogenetics, Multiplex Ligation-dependent 
Probe Amplification (MLPA) or Fluorescence In Situ Hybrid-
ization (FISH). To determine the origin of the imbalances, 
parental blood samples were requested and those avail-
able were tested by CMA, conventional cytogenetics or 
FISH, depending of the size of the imbalances. Informed 




Genomic DNA was extracted from peripheral blood lym-
phocytes using Illustra blood genomicPrep Mini Spin (GE 
Healthcare Life Sciences, Chalfont St Giles, Buckingham-
shire, UK) or NucleoSpin Blood (Macherey-Nagel, Düren, 
Germany) kit according to the manufacturers’ instructions. 
DNA concentration and purity were measured using a 
Qubit 3.0 Fluorometer (Thermo Fisher Scientific, Waltham, 
MA, USA) and BioDrop uLite Spectrophotometer (Isogen 
Life Science, De Meern, The Netherlands).
Chromosomal microarray
High-resolution whole genome analysis was performed us-
ing Agilent SurePrint G3 Unrestricted CGH ISCA v2 Human 
Genome microarrays according to the manufacturers’ in-
structions (Agilent Technologies, Santa Clara, CA, USA). The 
8x60 K oligonucleotide microarray format that contains ap-
proximately 60 000 sixty-mer probes with 60 kb average 
probe spacing, with a higher resolution within the region 
recommended by International Standard Cytogenomic 
Array (ISCA) Consortium, was used. Slides were scanned 
on a SureScan Dx Microarray scanner (Agilent Technolo-
gies, USA) and processed with Feature Extraction software 
(v12.0). Results were analyzed using Agilent CytoGenom-
ics (v3.0 and v4.0) software. The results were according to 
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tABle 1. Pathogenic copy number variations (CnVs) involving a single genomic region*
Patient no. ISCn description (2016)† Size (kb) Sex Age at examination (years) Id/dd ASd CA dysmorphism
99. 1p36.33p36.32(834101_2558913)x1 1724 F 6 x x x
5. 1q24.1-q25.1(166325047_176680992)x1 dn 10 356 M 5 x x x
8. 2p16.3(50886387_50947729)x1 61 F 6 x x
2. 2p16.3(50909765_50970721)x1 61 M 0 (1 month) x x x
30. 2p25.3(1788489_1973174)x3 185 F 13 x
19. 2q21.1(131501506_131915718)x1 mat 414 M 5 x x
51. 2q22.2q22.3(143931445_146479587)x1‡ 2548 M 12 x x x
25. 3p25.3(10150872_10309577)x1 159 F 11 x x
48. 3q26.31(176573342_178552807)x1 1979 F 0 (6 month) x x
73. 4p16.3(45882_686480)x3 pat 641 M 4 x
61. 4p16.3(72447_2747165)x1‡ 2675 F 8 x x
17. 4p16.3p16.1(72447_8732731)x1 dn‡ 8660 M 3 x x x x
103. 5p13.2(36520866_37406919)x3 dn 886 F 5 x x
96. 5p15.33p13.2(22149_35622770)x1 mat‡ 35 601 F 3 x x x
63. 6p25.2p24.2(3090209_11327673)x3 mat 8237 M 16 x x
68. 6q27(168682821_170921089)x1 2238 F 13 x x x
50. 7q11.23(72766313_74133332)x1‡ 1367 M 1 x x x
71. 7q35(145815487_145934608)x1 119 M 11 x
79. 8p22p21.3(13468338_23134996)x1 9667 M 7 x x
57. 8p23.1(7169490_12404062)x1‡ 5235 M 5 x x x
33. 8p23.3p11.1(191530_43529733)x3‡ 43 338 F 6 x x x
38. 8q23.1q24.12(109937640_120021371)x1 dn‡ 10 084 M 18 X x x
77. 8q23.3q24.11(117686699_118979648)x1‡ 1293 M 19 x x x
62. 9p24.3p13.1(204193_38741437)x3 38 537 M 8 x x x
46. 9p24.3p22.2(204193_16705259)x1 dn‡ 16 501 F 14 x x x
105. 9q34.3(140164421_141018984)x1‡ 855 M 4 x x x
39. 10q11.22q11.23(48364954_51780909)x3 3416 M 6 x x x
15. 10q23.31q23.32(92855758_93832017)x3 mat 976 M 5 x
40. 13q22.2q31.3(75400788_93036301)x1‡ 17 636 M 3 x x x
92. 15q11.2(22765628_23217514)x1 451 M 2 x
64. 15q11.2(22765628_23300287)x1 535 M 10 x x
106. 15q11.2(22765628_23300287)x1 535 M 5 x
85. 15q11.2q13.3(22765628_32899558)x3 dn 10 134 F 11 x x
3. 15q11.2q13.1(23656936_28520313)x1‡ 4863 M 2 x x
28. 15q11.2q13.1(23656936_28520313)x1 4863 F 17 x x x
60. 15q23q25.1(69058773_78855259)x1‡ 9797 M 11 x x x
58. 15q26.2q26.3(96869390_102383473)x1‡ 5514 F 7 x x
89. 15q26.3(99352805_102156616)x1‡ 2804 F 9 x x
80. 16p11.2(29673954_30190568)x3 517 F 10 x x x
13. 16q23.1q24.3(78387160_88755371)x1 10 368 M 12 x x
32. 17p11.2(16637902_20294038)x1 dn‡ 3656 M 8 x x x x
31. 17p12(14111772_15442066)x3 mat 1330 M 13 x
1. 17p13.3p13.1(24457_6566906)x3 6542 F 6 x
24. 17q21.31(43706886_44485830)x1 779 M 14 x x x
41. 17q24.1q24.3(62939944_68316019)x1 5376 F 1 x x x
47. 20q13.33(61704244_62908674)x1 1204 F 0 (1 month) x
45. 21q11.2q22.3(15485008_48090317)x3 32 605 M 6 x x x
67. 21q22.12q22.2(37635939_41718667)x3‡ 4083 F 3 x x x
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UCSC Human Genome build 19 (National Center for Bio-
technology Information build 37) and included imbalanc-
es with at least three consecutive probes with abnormal 
log2 ratios. UCSC genome browser (http://genome.ucsc.
edu), DECIPHER (DatabasE of Chromosomal Imbalances 
and Phenotypes using Ensembl Resources - http://deci-
pher.sanger.ac.uk/), PubMed (http://www.ncbi.nlm.nih.
gov/PubMed), ClinVar-NCBI (https://www.ncbi.nlm.nih.
gov/clinvar), OMIM (Online Mendelian Inheritance in Man 
- http://www.ncbi.nlm.nih.gov/omim) and Database of 
Genome Variants (http://projects.tcag.ca) databases were 
used in the interpretation of the results.
CNVs were categorized as pathogenic, benign and VOUS 
based on well-established microdeletion or microduplica-
tion regions, inheritance pattern, gene content, and size as 
described elsewhere (1,3). The term VOUS was used when 
variants were less than 300 kb and when or if they includ-
ed genes of unknown clinical significance and when family 
studies were inconclusive or unavailable.
ReSultS
In 73 patients, clinically relevant variants in the genome 
were detected and better characterized; there were 61 
microdeletions and 30 microduplications (Table 1). In 19 
patients, multiple imbalances were found (Table 2). Most 
of the pathogenic CNVs (68/91) were >1 Mb. VOUS were 
discovered in 35 patients: 25 had one VOUS, seven had 
two VOUS, and three subjects had one pathogenic CNV 
and one VOUS (subjects No. 49, 22, and 70). There were 17 
microdeletions and 25 microduplications (Table 3). Only 
seven of these 42 microdeletions and microduplica-
tions were >1Mb.
In the ID/DD, ASD, CA with/without dysmorphism group, 
there were only two patients with pathogenic CNVs. In the 
ID/DD, CA with/without dysmorphism group, there were 
47 subjects with pathogenic CNVs and nine with VOUS. In 
the ID/DD, ASD with or without dysmorphism group, five 
patients had pathogenic CNVs and six had VOUS. In the 
ID/DD, with or without dysmorphism group, there were 14 
patients with pathogenic CNVs and 11 with VOUS. There 
were five patients with pathogenic CNVs and four with 
VOUS in the CA with/without dysmorphism group, and 
only two patients with VOUS in the ASD with/without dys-
morphism group.
The distribution of 51 newly diagnosed pathogenic CNVs 
and 42 VOUS by size showed that there were no VOUS 
grater than 5 Mb (Table 4). The smallest CNV was hemizy-
gous deletion of 5 kb categorized as VOUS that partially 
encompasses ZNF41 gene in Xp11.23 region detected in 
three male patients. The largest imbalance was the dupli-
cation of 43 338 kb and included a whole 8p arm. A high 
resolution cytogenetic analysis revealed mosaic tetrasomy 
8p: 47,XX,i (8)(p10)[18]/46,XX[82].
Genomic regions that were the most commonly affected 
by pathogenic CNVs were 8p23 (6 patients), 15q11.2 (6 pa-
tients), and 22q11.21 (5 patients). In the group with com-
plex rearrangement, the most affected, relatively large re-
gion was 18q22.1q23 (5 patients).
Parents of 44 probands with pathogenic CNV or VOUS 
were available for DNA testing. Four VOUS were de novo 
and 16 were inherited. In eight cases, pathogenic CNVs 
were inherited from parents with balanced transloca-
tions, in seven cases one of the parent had same patho-
54. 22q11.21(18661724_21505417)x1 2844 M 0 (2 month) x x x
37. 22q11.21(18661724_21505417)x1 2844 M 3 x x x
59. 22q11.21q11.22(21505358_22905068)x1‡ 1400 M 3 x x x
34. 22q11.21(18706001_18984519)x3 mat 279 M 2 x x x
75. 22q13.31q13.33(46928208_51178264)x1‡ 4250 F 3 x x x
69. Xq28(153287517_153541289)x3 dn 254 F 2 x
*Abbreviations: CnVs - copy number variations; ISCn - International System for human Cytogenetic nomenclature; kb - kilobases; Id/dd - intellectual 
disability/developmental delay; ASd - autism spectrum disorders; CA - congenital anomalies; F – female; M – male; dn - de novo; mat - maternally 
inherited; pat - paternally inherited.
†In the ISCn report, monosomy/deletion/one copy is designated with x1 and trisomy/duplication/three copy is designated with x3 in the genome.
‡the patients in whom chromosomal imbalances have already been detected by high resolution conventional cytogenetics, MlPA (Multiplex 
ligation-dependent Probe Amplification) or FISh (Fluorescence In Situ hybridization). the results are according to uCSC human Genome build 19 
(national Center for Biotechnology Information build 37).
tABle 1. Continued. Pathogenic copy number variations (CnVs) involving a single genomic region*
Patient no. ISCn description (2016)† Size (kb) Sex Age at examination (years) Id/dd ASd CA dysmorphism
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genic CNV as his offspring, and 19 pathogenic CNVs were 
de novo.
dISCuSSIon
Pathogenic CNV were found in 43 of total 307 patients 
previously not tested by other cytogenetic or molecular 
methods or in whom these tests were negative for ge-
nomic imbalances, representing an overall diagnostic yield 
of 14%. Our results are in accordance with other studies on 
genome-wide oligonucleotide arrays (1,4,5). The diagnos-
tic yield is known to correlate with the array resolution and 
the genomic coverage of the array used. Currently, we are 
using 8x60K array with 60 kb overall median probe spac-
ing (higher in ISCA regions), and the results of this study 
showed that this platform is suitable for genetic testing of 
children with developmental disorders.
The microdeletion syndromes that were identified in 
more than one individual were: 15q11.2 deletion syn-
drome (MIM#615656)-3 patients, 22q11.21 deletion syn-
drome (MIM#188400; DiGeorge syndrome)-3 patients, 
4p16.3 deletion syndrome (MIM#194190; Wolf-Hirschhorn 
syndrome)-2 patients, 7q11.23 deletion syndrome 
(MIM#194050; Williams-Beuren syndrome)-2 patients, 
8q24.1 deletion syndrome (MIM#150230; Trichorhinopha-
langeal syndrome, type II)- 2 patients, 15q11.2q13.1 dele-
tion (MIM#105830; Angelman syndrome/MIM#176270; 
Prader-Willi syndrome)-2 patients, and 15q26-qter deletion 
syndrome (MIM#612626))-2 patients. Also, the same 61 kb 
deletion in 2p16.3 region disrupting NRXN1 gene was de-
tected in two patients.
One third of pathogenic CNVs ranged 1-5 Mb in size. Even 
though CNVs of <300 kb presented 21.6% of pathogenic 
CNVs, CNVs of this size were almost twice less presented 
in the category of pathogenic CNVs as compared to VOUS 
category. In pathogenic CNV category, there were twice 
more deletions than duplications, whereas microduplica-
tions were more frequent in VOUS category.
tABle 2. Pathogenic copy number variations (CnVs) involving two or more genomic regions*
Patient 
no. ISCn description (2016)† Size (kb) Sex
Age at 
examination 
(years) Id/dd ASdCA dysmorphia
20. 1p31.1(79322064_79541419)x1,22q11.21(18661724_21505417)x1 219/2844 M  3 x x x
56. 1p36.33p36.32(779727_5080691)x3,15q13.3(32065000_32509926)x3, 
21q22.3(46346682_48084156)x1‡
4301 /445/1737 M  9 x x x
78. 1q21.1q21.2(146507518_147824207)x1,16p11.2(28843773_29031059)x1 1317/187 M 15 x x x
11. 2q32.3q33.1(193.987.239_199.889.760)x1 dn, 2q33.2q33.3(203583507_205732083)x1 
dn, 2q34q35(209245201_216247586)x1 dn
5903/2149/7002 M  5 x x x
10. 2q37.3(239128062_243068396)x1 dn,9p24.3p13.3(204193_34206653)x3 dn‡ 3940/34 002 M  1 x x x
 9. 3p26.3p26.1(93949_6894668)x3 mat, 18q22.1q23(64900852_78012829)x1 mat‡ 6801/13 112 F 18 x x x
14. 4p16.3p16.1(45882_8732731)x3 dn,8p23.3p23.1(191530_6880363)x1 dn‡ 6689/8687 F 12 x x x
42. 4q32.2q35.2(162419540_190896674)x3 mat, 18q22.1q23(66312776_78012829)x1 mat‡ 28 477/11 700 F  3 x x x
91. 5p15.33(22149_2447692)x3 pat,18q22.1q23(61965606_78012829)x1 pat‡ 2426/16 047 M  1 x x
65. 5p15.33(22149_4163906)x1 mat,12p13.33p12.2(230421_20006466)x3 mat‡ 4142/19 776 F 13 x x x
27. 5q14.1q14.2(78490881_81768020)x3 dn,17q12(34856055_36248918)x1 mat 3277/1393 M  3 x x x
49. 7q11.23(72766313_73735597)x1, Xq28(154118643_154560375)x1 969/442 F  3 x x
83. 7q34q36.3(142328008_159124131)x1 mat, 18q23(76929981_ 78012829)x3 mat‡ 16 796/1083 F  2 x x x
22. 8p23.1(11384389_11586362)x3 mat, 11p15.1p11.2(18826790_43592489)x1 dn 202/24 766 F  1 x x
53. 8p23.3(1224868_1513649)x3, 8p23.3(1554187_1628286)x1 289/74 F  4 x x
16. 8p23.3p23.1(191530_8.079920)x1 pat, 12p13.33p13.31(230421_8309723)x3 pat‡ 7888/8079 M 10 x x x
 6. 12p13.33p13.32(230421_4939008)x1 pat, 22q13.31q13.33(45277037_51178264)x3 pat‡ 4709/ 5901 F 15 x x x
70. 17q12(34611352_36248918)x3, 18p11.31p11.23(6973010_805587)x3 1638/1083 M  2 x x
55. 18p11.32p11.23(148963_7983966)x1 dn, 18q21.2q23(52625076_78010032)x1 dn 7835/25 385 M  4 x x x
*Abbreviations: CnVs - copy number variations; ISCn - International System for human Cytogenetic nomenclature; kb - kilobases; Id/dd - intellectual disability/develop-
mental delay; ASd - autism spectrum disorders; CA - congenital anomalies; M – male; F – female; dn - de novo; mat - maternally inherited; pat - paternally inherited;.
†In the ISCn report, monosomy/deletion/one copy is designated with x1 and trisomy/duplication/three copy is designated with x3 in the genome.
‡the patients in whom chromosomal imbalances have already been detected by high resolution conventional cytogenetics, MlPA (Multiplex ligation-dependent Probe 
Amplification) or FISh (Fluorescence In Situ hybridization). In italic are designated variants of unknown clinical significance. the results are according to uCSC human 
Genome build 19 (national Center for Biotechnology Information build 37).
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VOUS were reported in 35 of 307 cases, including three cas-
es with additional pathogenic CNV. The sizes of the VOUS 
varied from 2387 kb to 5 kb. The largest VOUS was dupli-
cation in the 1q21.2 region inherited from the apparently 
healthy father. The duplication involved only one patho-
genic gene (GJA8) and partly affected the region causing 
1q21.1 duplication syndrome (#612475 MIM). It is con-
sidered that a critical region causing 1q21.1 duplication 
syndrome is 800 kb in size (chr1: 146577487-147394506 
GRCh37/ hg19) and includes at least 7 genes (6). Duplica-
tion in our patient overlapped only in 13 kb, and includ-
ed only GJA8 gene associated with cataract not present 
in the patient. Hence, although the duplication was rela-
tively large, it was classified as VOUS based on the gene 
content and the fact that it was inherited from the appar-
ently healthy father. The smallest CNVs on X chromosome 
detected in three male patients were inherited from the 
normal heterozygous mother in patients No.s 12 and 84. 
The most common size category of VOUS was <300 kb 
(40.5%). Based on the clinical presentation of our patients, 
tABle 3. Variants of unknown clinical significance involving one or more genomic region*
Patient 
no. ISCn description (2016)† Size (kb) Sex
Age at ex-
amination 
(years) Id/dd ASd CA dysmorphia
 36. 1p13.3(108332063_108739610)x3,16p13.3(3704209_3716095)x1 408/12 M  7 x x
 87. 1q21.1(145415190_145799602)x3 384 F 11 x x
 86. 1q21.1(145415190_145799602)x3 pat,1q21.2(147381357_149768855)x3 pat 384/2387 M  7 x x
 98. 1q32.3q41(214316368_215890520)x1 dn 1574 M  8 x x
 74. 1q43(242196930_242442157)x1 pat 245 M 14 x
 97. 2q37.3(239970755_240317187)x3 Xq13.2q13.3(73039814_74232626)x2 346/1193 M 13 x x x
  7. 3p26.3(2347184_2728530)x1 mat 381 F  3 x x x
 21. 3p26.3(2649825_2660973)x3 11 F  1 x
 94. 3p26.3p26.2(2309008_2815363)x3 506 M  2 x
 52. 3q25.1(148990670_149767161)x1 dn,10q24.1(97230835_97546470)x1 mat 776/316 F  9 x x
 44. 3q28(191413759_191931899)x3 pat 518 F  6 x x
 81. 6q14.3(87229264_87662392)x3 433 F  3 x
 76. 7q32.3q33(131707914_133070269)x3 1,362 M  3 x x
 66. 9q22.31(95410466_96011338)x1 601 F  5 x x x
 29. 10q23.1(84270008_84283542)x1, 22q11.22(23056562_23208022)x3 14/969 F  8 x x x
 90. 12q24.13q24.21(114277899_114518222)x3 mat 240 F  1 x x
 93. 15q11.2(22765628_23300287)x3 535 M  1 x
 88. 15q13.3(32065000_32509926)x3 pat 445 M  8 x x
 35 15q26.3(100569135_102383473)x1 mat 1814 F  5 x x x
 23. 16p13.11(14910205_16194578)x3 pat 1676 F  5 x
  4. 16p13.3(6991421_7036068)x1 45 M  2 x x
100. 16q23.1(77351997_78187104)x3 835 M  1 x x x
 95. 21q22.3 (45814926_46505455)x3 691 M  8 x x
 26. 22q11.23(23895563_24178173)x3 283 F  8 x x x
 12. Xp11.23(47330212_47335227)x0 mat, Xq13.3(74463757_74651249)x2 mat 5/187 M  7 x x x
 18. Xp11.23(47330212_47335227)x0 5 M  3 x
 84. Xp11.23(47330212_47335227)x0 mat 5 M  9 x x x
101. Xp22.2(13945712_14167313)x0 dn,4q22.3(98501338_98757811)x1 mat 221/256 M 10 x x x
 72. Xp22.33(3313941_3911921)x1 dn 598 F  1 x
 82. Xq21.1(77105411_77127453)x2 22 M 21 x
104. Xq21.1(79777911_79932626)x2 155 M  3 x x
102. Xq26.2(130674304_130950243)x2 mat 276 M  3 x x x
*Abbreviations: ISCn - International System for human Cytogenetic nomenclature; kb - kilobases; Id/dd - intellectual disability/developmental 
delay; ASd - autism spectrum disorders; CA - congenital anomalies; M – male; F – female; dn - de novo; mat - maternally inherited; pat - paternally 
inherited.
†In the ISCn report, monosomy/deletion/one copy is designated with x1, trisomy/duplication/three copy is designated with x3 in the genome, with 
x0 deletion on X chromosome in a male subject, and with x2 duplication on X chromosome in a male subject. the results are according to uCSC hu-
man Genome build 19 (national Center for Biotechnology Information build 37).
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family studies, type of CNV (deletion vs duplication), gene 
content, and the size distribution of pathogenic CNVs and 
VOUS, we recommend using a 300 kb as an arbitrary cut 
off for clinically relevant CNV when using this platform.
The inheritance pattern of a CNV, when accompanied by 
clinical and family history information, can be useful. How-
ever, in the clinical setting can sometimes be difficult to 
test both parents. De novo CNVs are more likely than in-
herited CNVs to be pathogenic. In this study, of 15 de novo 
CNVs, 13 were pathogenic and only two were VOUS.
The inherited CNVs may cause a range of severity of clini-
cal presentation. In four of seven cases where one of the 
parent had the same pathogenic CNV as offspring, parents 
were phenotypically normal (patients No. 19, 73, 15, and 
34), in two cases clinical presentation was milder (patients 
No. 63 and 27) and in one case the mother had same phe-
notype (patient No. 31). This can be exemplified by case 63, 
where the male patient inherited dup 6p25.2p24.2 from 
his mother. Distal 6p trisomy is very rare. Patients have vari-
able clinical findings with duplications that usually range 
from 6pter to 6p21-6p25 (7). The phenotypic features that 
are associated with dup 6p25.2p24.2 that were present in 
our patient were tall stature, dysmorphia, obesity, frequent 
respiratory infections, foot malformations, hypoplastic left 
kidney, hypospadias, and urethral stenosis. His 37-year old 
mother was dysmorphic, obese like her son, but had no 
associated anomalies. In addition, she suffered from osteo-
petrosis and polyarthralgia, which are presumably of differ-
ent etiology. Despite the large duplications, both had com-
pletely normal intellectual functioning.
The CNVs that contain many genes or known disease 
genes are more likely to be pathogenic than those that 
contain few genes or genes of uncertain function. Thus, 
large CNVs are more likely than small CNVs to cause clin-
ical manifestations as they generally encompass more 
genes, with a higher probability to affect a dosage-sen-
sitive one. As deletions result in haploinsufficiency, some 
very small deletions, for example 61 kb deletion in 2p16.3 
region altering NRXN1 gene (patients No. 8 and 2), can also 
be pathogenic (8). Duplications are more difficult to inter-
pret because some relatively large duplications have no 
pathogenic effect and are found in normal subjects. CNVs 
within regulatory regions of clinically relevant genes make 
interpretation even more complex. In the patient No. 11, 
CMA analysis found three consecutive deletions in region 
2q32.3q35. The analysis of subtelomeric regions and mi-
crodeletion syndromes by MLPA method was negative. 
Most of his phenotypic features overlapped with the clini-
cal presentation of 2q33.1 syndrome (MIM # 612313, Glass 
syndrome). The gene SATB2 was not directly affected by 
the deletion in region 2q33.1. For this reason, the MLPA 
analysis using P245-B1 kit targeting within the 2q33.1 re-
gion only gene SATB2 was negative. The first deletion of 
2q32.3-33.1 had a distal break point between genes PLCL1 
and SATB2. This probably led to a disruption of SOX9- medi-
ated cis-regulation resulting in functional haploinsufficien-
cy of SATB2 (9).
The retrospective study of 30 patients by CMA analysis 
successfully confirmed all previously detected genomic 
changes. The genomic breakpoints and the gene content 
were defined, allowing for more precise genotype-pheno-
type delineation. Furthermore, some additional changes 
were found in patient No. 56 in whom 15q13.3 duplica-
tion of 445 kb was not detected by MLPA, and in patients 
No.s 83 and 91, in whom 18q23 duplication of 1083 kb and 
5p15.33 duplication of 2426 kb, respectively, were missed 
by chromosome karyotyping. This discordance may be ex-
plained by targeted analysis of the genome provided by 
MLPA probes and a small resolution of the conventional 
karyotyping, usually 5-10 Mb.
The major difference between patients with pathogenic 
CNVs and patients with VOUS was present in groups with 
ID/DD, ASD, CA with/without dysmorphism; ID/DD, CA 
with/without dysmorphism; and ASD with/without dysmor-
phism. This was expected, considering the size and number 
of pathogenic genes encompassed by pathogenic CNVs. 
ASD with/without dysmorphism was present in seven pa-
tients with pathogenic CNVs only in combination with ID/
DD and/or CA and in the VOUS group, it was twice as fre-
quent as in the group with pathogenic CNVs. Subsets of 
individuals with ASD are more likely to carry disruptive de 
novo and rare CNVs and sequence-level mutations (10). 
Microarray testing identifies etiology of ASD in 8%-
tABle 4. Size distribution of pathogenic copy number varia-
tions (CnVs) and variants of unknown clinical significance 






>10 Mb  7 (13.7)  0
5-10 Mb  7 (13.7)  0
1-5 Mb 16 (31.4)  7 (16.7)
1 Mb-500 kb  8 (15.7)  9 (21.4)
500-300 kb  2 (3.9)  9 (21.4)
<300 kb 11 (21.6) 17 (40.5)
Total 51 (100.0) 42 (100.0)
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21% of cases. Overall, CMA may identify a clinically signifi-
cant CNV in about 10% of all cases of ASD (11). Whole exome 
sequencing (WES) and whole genome sequencing (WGS) 
are expected to increase significantly the diagnostic yield 
when applied to patients with ASD. A recent report sug-
gests that WES/WGS may identify an additional 10%–15% 
of causes of ASD. Together WES and CMA may identify the 
cause of ASD in 20% of cases (12). Hence, further testing of 
ASD subjects with next generation sequencing technique is 
the next step in our genetic testing protocol.
In summary, our results showed that Agilent ISCA v2 Hu-
man Genome 8x60 K oligonucleotide microarray format 
provided reasonable resolution for clinical use, particularly 
in the ISCA regions containing known disease genes asso-
ciated with well-established phenotypes. The CMA meth-
od revised the MLPA and conventional karyotyping results 
and provided a new, more detailed insight into genomic 
changes. It is to be expected that increasing number of 
smaller pathogenic CNVs will be discovered because there 
is a tendency for an increasing number of laboratories to 
use CMA platforms of higher resolution. This will simul-
taneously lead to an increased number of VOUS and the 
need to include other criteria for establishing their signif-
icance, based on data collection on new patients, geno-
type-phenotype correlation, and better understanding of 
the complex interaction of the genes included in the CNVs 
with the entire genome.
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